Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon α in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment

@article{Huland1994InhaledII,
  title={Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon α in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment},
  author={Edith Huland and Hans Heinzer and Hartwig Huland},
  journal={Journal of Cancer Research and Clinical Oncology},
  year={1994},
  volume={120},
  pages={221-228}
}
We describe here a mainly topical interleukin-2 (IL-2) application in pulmonary metastatic renal-cell carcinoma: a high-dose long-term inhalation of IL-2 (90% of IL-2 dose) and low-dose systemic subcutaneous IL-2 (10% of IL-2 dose) and systemic subcutaneous interferon α (IFN α). The effectiveness of this treatment is remarkable. No pulmonary metastases progressed during treatment. One complete response, 8 partial responses, and 6 cases of stable disease were achieved in the lungs of the 15… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Aerosolized natural interleukin 2 for treatment of advanced malignancy: results of a phase I trial

  • WE Aulitzky, M Kessler, M Wilhelm, E Huland
  • Ann Hematol
  • 1993
1 Excerpt

Low dose continuous infusion recombinant human interlenkin-2 (rhIL-2) and roferon; an active outpatient regimen for metastatic renal-cell carcinoma (RCCa)

  • R Figlin, M Citron, R Whitehead
  • Proc Annu Meet Am Soc Clin Oncol 9:A553
  • 1990

Low-intensity" combination treatment with r-interleukin-2 (rh-IL-2) and r-interferon alfa-2a (rh-IFN-a-2a) in renal-cell carcinoma. A multicenter phase II trial

  • A Lindemann, JRT Monson, RA Stahel
  • Proc Annu Meet Am Soc Clin Oncol 9:A584
  • 1990

Phase II trial of recombinant interleukin-2 (IL-2) and roferon A (IFN) in patients (PTS) with advanced renal-cell carcinoma

  • C Mittelman, C Puccio, T Ahmed
  • Proc Annu Meet Am Soc Clin Oncol 9:A736
  • 1990

Sequential therapy of recombinant interferon alpha (IFN-A) and recombinant interleukin-2 (IL-2) in patients with advanced renal-cell carcinoma (RCC)

  • HH Baxtsch, M Adler, RH Ringert
  • Proc Annu Meet Am Soc Clin Oncol 9:A556
  • 1990

High dose interleukin-2 without lymphokine activated killer cells. Inactive in advanced renal-cell cancer

  • J Abrams, A Rayner, A Wiernik, D Parkinson
  • Proc Am As soc Cancer Res
  • 1989

Similar Papers

Loading similar papers…